{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:46:54Z","timestamp":1782805614264,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Merck and Co"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12955-016-0566-8","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T10:40:59Z","timestamp":1480329659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Estimation of utility weights for human papilloma virus-related health states according to disease severity"],"prefix":"10.1186","volume":"14","author":[{"given":"Minsu","family":"Ock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Yeol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Seung","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-1318","authenticated-orcid":false,"given":"Min-Woo","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"566_CR1","unstructured":"World Health Organization, Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx . Accessed Feb 27 2015."},{"issue":"1","key":"566_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","volume":"13","author":"EH1 Elbasha","year":"2007","unstructured":"Elbasha EH1, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28\u201341.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"566_CR3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","volume":"6","author":"LL Villa","year":"2005","unstructured":"Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271\u20138.","journal-title":"Lancet Oncol"},{"issue":"19","key":"566_CR4","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928\u201343.","journal-title":"N Engl J Med"},{"issue":"19","key":"566_CR5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"FUTURE II Study Group","year":"2007","unstructured":"FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915\u201327.","journal-title":"N Engl J Med"},{"issue":"9576","key":"566_CR6","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","volume":"369","author":"KA Ault","year":"2007","unstructured":"Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861\u20138.","journal-title":"Lancet"},{"issue":"9679","key":"566_CR7","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","volume":"373","author":"N Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz N, Manalastas Jr R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949\u201357.","journal-title":"Lancet"},{"issue":"11","key":"566_CR8","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95","author":"LL Villa","year":"2006","unstructured":"Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459\u201366.","journal-title":"Br J Cancer"},{"key":"566_CR9","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","volume":"339","author":"JJ Kim","year":"2009","unstructured":"Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.","journal-title":"BMJ"},{"key":"566_CR10","doi-asserted-by":"crossref","unstructured":"Kim Y, Ahn J, Kim YJ, Park J, Kim J, Lee YJ, et al. Economic Evaluation of HPV Vaccination. National Evidence-based Healthcare Collaborating Agency, 2013. In Korean","DOI":"10.1016\/j.jval.2013.08.533"},{"issue":"5","key":"566_CR11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/heapol\/czl018","volume":"21","author":"F Sassi","year":"2006","unstructured":"Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006;21(5):402\u20138.","journal-title":"Health Policy Plan"},{"key":"566_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5\u201321.","journal-title":"Br Med Bull"},{"issue":"2","key":"566_CR13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ygyno.2010.05.002","volume":"118","author":"M Kuppermann","year":"2010","unstructured":"Kuppermann M, Melnikow J, Slee C, Tancredi DJ, Kulasingam S, Birch S, et al. Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions. Gynecol Oncol. 2010;118(2):108\u201315.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"566_CR14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/hec.1278","volume":"17","author":"K Howard","year":"2008","unstructured":"Howard K, Salkeld G, McCaffery K, Irwig L. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ. 2008;17(5):593\u2013605.","journal-title":"Health Econ"},{"issue":"10","key":"566_CR15","first-page":"849","volume":"51","author":"J Melnikow","year":"2002","unstructured":"Melnikow J, Kuppermann M, Birch S, Chan BK, Nuovo J. Management of the low-grade abnormal Pap smear: What are women's preferences? J Fam Pract. 2002;51(10):849\u201355.","journal-title":"J Fam Pract"},{"issue":"8","key":"566_CR16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.clinthera.2011.06.012","volume":"33","author":"FS Mennini","year":"2011","unstructured":"Mennini FS, Panatto D, Marcellusi A, Cristoforoni P, De Vincenzo R, Di Capua E, et al. Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy. Clin Ther. 2011;33(8):1084\u20131095.e4.","journal-title":"Clin Ther"},{"issue":"4","key":"566_CR17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jval.2010.11.017","volume":"14","author":"EL Jewell","year":"2011","unstructured":"Jewell EL, Smrtka M, Broadwater G, Valea F, Davis DM, Nolte KC, et al. Utility scores and treatment preferences for clinical early-stage cervical cancer. Value Health. 2011;14(4):582\u20136.","journal-title":"Value Health"},{"issue":"1","key":"566_CR18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clinthera.2014.11.002","volume":"37","author":"A Marcellusi","year":"2015","unstructured":"Marcellusi A, Capone A, Favato G, Mennini FS, Baio G, Haeussler K, et al. Health utilities lost and risk facto+rs associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group. Clin Ther. 2015;37(1):156\u2013167.e4.","journal-title":"Clin Ther"},{"issue":"7","key":"566_CR19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0277-9536(91)90303-T","volume":"32","author":"DC Hadorn","year":"1991","unstructured":"Hadorn DC. The role of public values in setting health care priorities. Soc Sci Med. 1991;32(7):773\u201381.","journal-title":"Soc Sci Med"},{"issue":"2","key":"566_CR20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3961\/jpmph.2008.41.2.80","volume":"41","author":"EY Bae","year":"2008","unstructured":"Bae EY. Guidelines for economic evaluation of pharmaceuticals in Korea. J Prev Med Public Health. 2008;41(2):80\u20133. Korean.","journal-title":"J Prev Med Public Health"},{"issue":"7","key":"566_CR21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/hec.760","volume":"12","author":"P Dolan","year":"2003","unstructured":"Dolan P, Olsen JA, Menzel P, Richardson J. An inquiry into the different perspectives that can be used when eliciting preferences in health. Health Econ. 2003;12(7):545\u201351.","journal-title":"Health Econ"},{"issue":"2","key":"566_CR22","first-page":"207","volume":"29","author":"A Gafni","year":"1994","unstructured":"Gafni A. The standard gamble method: what is being measured and how it is interpreted. Health Serv Res. 1994;29(2):207\u201324.","journal-title":"Health Serv Res"},{"issue":"10","key":"566_CR23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0277-9536(96)00271-7","volume":"44","author":"P Dolan","year":"1997","unstructured":"Dolan P, Sutton M. Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. Soc Sci Med. 1997;44(10):1519\u201330.","journal-title":"Soc Sci Med"},{"issue":"3","key":"566_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hec.834","volume":"13","author":"JA Salomon","year":"2004","unstructured":"Salomon JA, Murray CJ. A multi-method approach to measuring health-state valuations. Health Econ. 2004;13(3):281\u201390.","journal-title":"Health Econ"},{"issue":"9173","key":"566_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(98)07507-2","volume":"354","author":"TB Ust\u00fcn","year":"1999","unstructured":"Ust\u00fcn TB, Rehm J, Chatterji S, Saxena S, Trotter R, Room R, et al. Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO\/NIH Joint Project CAR Study Group. Lancet. 1999;354(9173):111\u20135.","journal-title":"Lancet"},{"issue":"9","key":"566_CR26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0277-9536(91)90156-7","volume":"32","author":"IS Breetvelt","year":"1991","unstructured":"Breetvelt IS, Van Dam FS. Underreporting by cancer patients: the case of response-shift. Soc Sci Med. 1991;32(9):981\u20137.","journal-title":"Soc Sci Med"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-016-0566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T21:11:43Z","timestamp":1568581903000},"score":1,"resource":{"primary":{"URL":"http:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-016-0566-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1186\/s12955-016-0566-8","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]},"article-number":"163"}}